Discover Neuroactive Compounds with Whole-Organism Behavioral Readouts

Q: How do you ensure that behavioral effects are specific to neuroactivity rather than general toxicity?

We include counter-screens for overall viability (e.g., touch response, heart rate) and compare behavioral changes to known toxicants. Compounds that cause broad developmental arrest or death are excluded. Additionally, we often include a set of reference neuroactive drugs to calibrate the behavioral signatures expected for true neuroactivity.

Neuroactive Compound Screening in Larval Zebrafish

Accelerate CNS drug discovery with high-throughput, in vivo behavioral phenotyping.

The larval zebrafish (Danio rerio) has become a powerful vertebrate model for identifying compounds that modulate nervous system activity. At only timeline scoped per project after consultation post-fertilization, each larva is optically transparent, small enough to fit in a 96- or 384-well plate, and exhibits a rich repertoire of behaviors—including spontaneous locomotion, startle responses, thigmotaxis, and seizure-like events—that can be quantified in real time.

Our neuroactive compound screening service combines automated compound delivery, high-speed video tracking, and advanced statistical or machine-learning classifiers to profile the behavioral effects of large libraries. By capturing the integrated output of an intact vertebrate nervous system, this approach reveals effects—such as sedation, hyperexcitability, or anxiolysis—that cannot be recapitulated in cell-based or biochemical assays.

Whether you are screening for antiseizure candidates, investigating neurodevelopmental phenotypes, or prioritizing hits from a large chemical library, our platform provides the throughput and translational relevance needed to make informed decisions early in the drug discovery pipeline.

Trusted in High-Profile Screens Larval zebrafish behavioral screens have identified hundreds of neuroactive compounds and enabled the clustering of drugs by shared behavioral signatures, as demonstrated in landmark studies (;;.

Why Choose Our Zebrafish Neuroactive Screening Service?

Combine throughput with in vivo complexity to uncover meaningful neuroactive hits.

Behavioral Depth

Real-Time Whole-Organism Readout

Capture a multidimensional behavioral response—locomotion, burst activity, turning, and startle amplitude—from each larva. This provides a rich phenotypic fingerprint that can distinguish compound classes with subtle differences in mechanism.

Scale

High-Throughput Format

Arrayed in standard multiwell plates, our platform can profile hundreds to thousands of compounds per campaign. Automated liquid handling and parallel recording minimize variability and accelerate hit identification.

Relevance

Vertebrate Model with Conserved Neurobiology

Zebrafish share key neurotransmitter systems and neural circuit motifs with mammals. Behavioral effects observed in larvae are predictive of outcomes in rodent models, offering a cost-effective bridge between in vitro assays and preclinical testing.

How It Works: Behavioral Phenotyping In Vivo

Leveraging the larval zebrafish for rapid, scalable neuroactivity detection.

Whole-Organism Integration

Unlike cell-based assays, larval zebrafish allow the compound to act on the entire nervous system, including sensory, motor, and integrative circuits. The resulting behavior reflects the net effect of all physiological interactions.

Optical Transparency Enables Real-Time Tracking

Larvae are optically transparent, so infrared backlighting and high-speed cameras can capture movement without any invasive procedures. This allows continuous recording of multiple behavioral endpoints over hours.

Multiparametric Feature Extraction

Automated software extracts dozens of features per larva—distance traveled, velocity, turning frequency, thigmotaxis index, startle latency, and more. This multiparametric space improves the ability to cluster compounds by mechanism.

Machine Learning Classification

Recent advances apply deep metric learning and other classifiers to high-replicate behavioral data, enabling both supervised hit identification and unsupervised discovery of compound clusters with shared bioactivity.

Controlled Exposure Conditions

Compounds are added directly to the aqueous medium at defined concentrations. The small body size ensures rapid uptake, while the chorion (if present) can be removed to facilitate permeability. Exposure duration is optimized per project.

Why Zebrafish? A Comparison with Other Models

Understand the trade-offs in throughput, complexity, and translational relevance.

Feature	Larval Zebrafish	Rodent Models	Cell-Based Assays	Organoids
Throughput (compounds per week)	High (hundreds)	Low (tens)	High (thousands)	Low (tens)
Whole-organism neurobiology	Integrated CNS in vivo	Full CNS in vivo	No CNS integration	Partial circuitry
Optical transparency for real-time imaging	Yes (larval stage)	No (invasive methods required)	Yes (single-cell level)	Partial (thick tissue limits depth)
Cost per compound	Low	High	Very low	Moderate–High
Ethical/regulatory burden	Low (larval stages not protected)	High (licensed procedures)	Minimal (in vitro)	Minimal (in vitro)
Genetic amenability	Yes	Yes (extensive tool set)	Yes (easy to manipulate)	Yes (iPSC-derived)
Availability of behavioral endpoints	Rich (locomotion, startle, social)	Rich (open field, maze, swim test)	None (no behavior)	None (no integrated behavior)
Predictivity of human neurotoxicity	Moderate–High (conserved pathways)	High (mammalian physiology)	Low (isolated targets)	Moderate (3D human tissue)

Our Screening Workflow

A streamlined process from compound exposure to actionable hit lists.

1

Compound Administration

Larvae at optimized developmental stages (e.g., 5–7 dpf) are arrayed in multiwell plates. Compounds are added via automated liquid handling, and the plate is placed in a controlled environment (temperature, light cycle) for a defined exposure period (typically 1–24 h depending on project needs).

Automated compound addition to larval zebrafish in a 96-well plate.

→

2

Behavioral Recording

Using high-speed infrared video cameras, we record spontaneous and evoked behaviors from each well simultaneously. larvae per plate are tracked in real time, capturing parameters such as distance traveled, velocity, turn angle, burst frequency, and startle response amplitude.

Multiwell plate under infrared recording for simultaneous behavioral tracking.

→

3

Hit Identification & Reporting

Specialized software extracts feature vectors per larva, then statistical models or machine learning classifiers (e.g., metric learning) compare treated groups to vehicle controls. Hits are prioritized based on effect size, dose responsiveness, and behavioral signature similarity to known neuroactive compounds.

Behavioral feature heatmap and hit list from a representative screen.

Data Analysis Pipeline & Deliverables

From raw video to interpretable behavioral profiles and hit lists.

Bioinformatics Pipeline Steps

Video Preprocessing — Raw video files are segmented per well and corrected for background noise, plate movement, and lighting artifacts.
Feature Extraction — For each larva, we compute >20 behavioral parameters including total distance, average velocity, thigmotaxis index, turn angle, burst frequency, startle latency, and response amplitude.
Quality Control & Normalization — Outlier wells (e.g., dead larvae, plate edge effects) are flagged and removed. Data are normalized to plate-specific vehicle controls to account for batch variation.
Statistical Hit Calling — Compound wells are compared to controls using analysis of variance (ANOVA) or mixed-effects models, with false discovery rate (FDR) correction for multiple testing.
Machine Learning Clustering (Optional) — For large libraries, we apply deep metric learning or t-SNE/UMAP embedding to cluster compounds by behavioral phenotype, revealing shared mechanisms of action.
Hit Prioritization & Report Generation — A final hit list with effect sizes, dose-response curves, and behavioral summaries is generated, along with interactive visualizations for exploratory analysis.

Primary Output

Behavioral Screening Report

Summary of experimental design (compound library, concentrations, replicates)
Per-compound behavioral feature tables with statistical significance
Hit list ranked by effect magnitude and consistency across replicates
Cluster maps or dendrograms (when ML clustering is applied)

Raw Data

Video and Tracking Files

Raw video recordings (compressed format) for each plate
Per-larva tracking data (position/time series) in CSV or HDF5 format
Normalized feature matrix with all QC flags

Applications in CNS Drug Discovery

Our service supports multiple stages of the drug development pipeline.

1

Antiepileptic Drug Discovery

Use pentylenetetrazole (PTZ)-induced seizure models in zebrafish larvae to screen compounds for antiseizure activity. Behavioral endpoints such as convulsion-like movements and seizure latency are quantified, providing a rapid surrogate for mammalian seizure models.

2

Neurodevelopmental Phenotype Rescue

In genetically modified lines recapitulating autism or intellectual disability, larvae often display altered locomotion, startle habituation, or social interaction deficits. Our platform can test hundreds of compounds for their ability to normalize these behavioral anomalies.

3

Proconvulsant Risk Assessment

Early-stage safety profiling to flag compounds that induce seizure-like behavior. This is critical for drugs targeting the CNS or those with predicted central nervous system exposure.

4

Psychoactive Compound Profiling

Classify novel chemical entities by their behavioral signature—sedative, stimulant, hallucinogen-like, or anxiolytic—using reference libraries of known neuroactive drugs (e.g., the set of 650 CNS-active compounds from.

Project Details: Materials and Timelines

Each project is scoped individually; representative guidelines below.

Project Type	Material Provided	Suggested Amount	Typical Timeline
Single-dose primary screen (up to 100 compounds)	Compound library in DMSO (10 mM stock)	5–10 µL per compound	Per project
Dose-response characterization (top hits)	Same as above; additional plates	6–8 dose points, 3 replicates	Per project
Custom transgenic or mutant line evaluation	Zebrafish line (embryos or founder adults)	≥200 embryos per line	Per project
Large library screen (500–2,000 compounds)	Pre-plated library in standard format	20 µL per well per concentration	Per project
Mechanistic validation with known reference compounds	Reference compounds (list provided)	5–10 mg each	Per project

What You Receive

Standard deliverables for every neuroactive screening project.

Complete study protocol with experimental conditions detailed.

Raw video files and tracking coordinates for each well.

Per-larva and per-compound behavioral feature tables (CSV format).

Statistical analysis report including hit list with p-values and effect sizes.

Dose-response curves for validated hits (when applicable).

Interactive cluster visualization (if machine learning analysis is included).

Method summary suitable for inclusion in publications or regulatory submissions.

Frequently Asked Questions

Get answers to common questions about zebrafish neuroactive compound screening.

What larval age is typically used for behavioral screening?

We most commonly use larvae at timeline scoped per project after consultation post-fertilization (dpf). At this stage, the nervous system is functional, larvae display robust spontaneous and evoked behaviors, and they are small enough for high-density multiwell formats. Age can be adjusted for specific developmental windows if required.

How do you ensure that behavioral effects are specific to neuroactivity rather than general toxicity?

We include counter-screens for overall viability (e.g., touch response, heart rate) and compare behavioral changes to known toxicants. Compounds that cause broad developmental arrest or death are excluded. Additionally, we often include a set of reference neuroactive drugs to calibrate the behavioral signatures expected for true neuroactivity.

Can you screen compounds that are not soluble in DMSO?

Yes. We can accommodate compounds in other vehicles (water, ethanol, etc.) as long as the final concentration of the vehicle does not exceed a tolerated level. For compounds with low solubility, we can perform suspension or sonication steps prior to addition. Each case is evaluated during the study design phase.

What throughput can I expect for a typical project?

Throughput depends on the number of replicates and assay complexity. A single-concentration primary screen can cover hundreds to a few thousand compounds per week using a 96- or 384-well format. For dose-response confirmation, the number is lower. Exact timelines are scoped per project to match your compound library size and desired statistical power.

How are behavioral data linked to compound mechanism?

By profiling hundreds of known neuroactive compounds, we can build a reference behavioral space. New compounds with similar behavioral signatures are predicted to share mechanism-related pathways. This approach has been validated in studies that correctly grouped drugs acting on the same neurotransmitter receptor or ion channel (;.

Do you offer transgenic or mutant zebrafish lines for specific disease modeling?

Yes, we can use your provided transgenic line or generate custom lines for screening. For example, we have experience with F0 knockout models created via CRISPR/Cas9 to rapidly generate epilepsy or autism-relevant phenotypes for compound testing (ZeClinics, 2024). One-time line generation is scoped separately from screening.